A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
Commentary|Articles|February 3, 2026
Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions
In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.
Advertisement
Advertisement
Women with multiple sclerosis often navigate reproductive health, pregnancy, and menopause alongside ongoing disease management. Hormonal changes, family planning decisions, and life stage transitions can influence symptoms, treatment timing, and overall wellbeing. A care approach that integrates neurologic and women’s health considerations helps ensure management strategies align with both disease control and personal health goals.1
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Here's some of what is coming soon to NeurologyLive® this week.
Emerging therapies for muscular dystrophy are targeting a range of disease mechanisms, from RNA-based approaches and muscle-directed delivery to cell therapy and DUX4 suppression.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
Advertisement
Advertisement